SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel TEL AVIV, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced the submission of an Investigational New Dr ...

Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and cannabinoid pharmaceuticals [5] - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder (ASD) [5] Recent Developments - MitoCareX Bio Ltd., a venture of SciSparc, has appointed Professor Nir Peled to its scientific advisory board, enhancing its expertise in cancer therapeutics [1][4] - MitoCareX is focused on drug discovery targeting the mitochondrial SLC25 protein family, with recent validation of its target using Non-Small Cell Lung Cancer (NSCLC) cells [4] Research and Contributions - Professor Peled is a recognized expert in thoracic oncology with over 250 peer-reviewed publications, contributing significantly to lung cancer research and treatment [2][3] - His work includes personalized targeted therapy, immunotherapy, biomarker development, and early detection of lung cancer [3] Technological Advancements - MitoCareX has utilized advanced computational drug discovery platforms, including the proprietary MITOLINE™ algorithm, to screen millions of small molecules for potential anti-cancer treatments [4]

Core Viewpoint - SciSparc Ltd. is advancing its clinical trial for SCI-210, a treatment for autism spectrum disorder (ASD), with the first five patients enrolled in Israel, aiming for commercialization in the Israeli market first [1][3]. Group 1: Clinical Trial Details - The ongoing clinical trial is a double-blind, randomized, and placebo-controlled study involving 60 subjects aged 5 to 18 over a 20-week period [2]. - The trial will assess the efficacy of SCI-210, which combines cannabidiol (CBD) and CannAmide™, against standard CBD monotherapy in managing ASD symptoms [2][3]. - Primary efficacy metrics include the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, Clinical Global Impressions-Improvement (CGI-I) by clinicians, and effective therapeutic dose [3]. Group 2: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with other drug development programs targeting Tourette Syndrome, Alzheimer's disease, and pain management [6]. - The company is led by an experienced team and aims to enhance its portfolio of technologies and assets based on cannabinoids [6]. Group 3: ASD Context - Autism spectrum disorder (ASD) affects social interaction and communication, with a wide range of symptoms and severity [5]. - Treatments and services can improve symptoms and daily functioning for individuals diagnosed with ASD [4].

SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met TEL AVIV, Israel, Aug. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has signed an Exclusive Patent License Agreement (the "License Agreement") with Polyriz ...

SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's approval of AutoMax's petition to convene special class meetings of its shareholders to approve the Merger with the Company TEL AVIV, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous syste ...

SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI TEL AVIV, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that a new article published ...

NSCLC is the most typical form of lung cancer and, according to ResearchAndMarkets.com, the NSCLC Market is projected to reach a value of $59.77 billion by the year 2030. Accounting for 80%-85% of all lung cancer cases globally, NSCLC has driven key market players to focus on continuous innovation and efficacy enhancement in therapeutics. This prominence is due to lung cancer's status as one of the most common cancers worldwide, contributing to a significant number of global deaths. Previously, MitoCareX Bi ...

About SciSparc Ltd. (Nasdaq: SPRC): This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential significant role of MitoCareX's drug target in NSCLC, the projected size of the NSCLC market, and that MitoCareX's AI model is expected to enable MitoCareX to navigate broader chemical spac ...

SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has signed a non-binding letter of intent ("LOI") with an undisclosed biotechnology company to pursue the out-licensing of its SCI-160 p ...

SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has signed a non-binding letter of intent ("LOI") with an undisclosed biotechnology company to pursue the out-licensing of its SCI-160 p ...